Trial Profile
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Ureteral neoplasms; Urogenital cancer
- Focus Therapeutic Use
- 27 Jan 2024 Extended follow-up results assessing safety and efficacy of gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma presented at the 2024 Genitourinary Cancers Symposium
- 22 Apr 2023 Planned End Date changed from 31 Aug 2023 to 20 Apr 2024.
- 13 Jul 2022 Planned End Date changed from 31 Aug 2022 to 31 Aug 2023.